Table of Contents
ISRN Oncology
Volume 2011, Article ID 732452, 4 pages
http://dx.doi.org/10.5402/2011/732452
Case Report

Multiple Endocrine Neoplasia 2a Presenting with Pheochromocytoma and Pituitary Macroadenoma

Department of Urology, University of Oklahoma Health Sciences Center, 920 Stanton L. Young Boulevard, WP 3150, OK 73104-5036, USA

Received 15 February 2011; Accepted 24 March 2011

Academic Editors: A. M. Garcia-Lora, A.-B. Jacobsen, A. E. Pinto, and A. Scorilas

Copyright © 2011 Jonathan E. Heinlen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Akerstrom and P. Stalberg, “Surgical management of MEN-1 and -2: state of the art,” Surgical Clinics of North America, vol. 89, no. 5, pp. 1047–1068, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Raue, J. L. Kraimps, H. Dralle et al., “Primary hyperparathyroidism in multiple endocrine neoplasia type 2A,” Journal of Internal Medicine, vol. 238, no. 4, pp. 369–373, 1995. View at Google Scholar · View at Scopus
  3. R. Humphrey, D. Gray, S. Pautler, and W. Davies, “Laparoscopic compared with open adrenalectomy for resection of pheochromocytoma: a review of 47 cases,” Canadian Journal of Surgery, vol. 51, no. 4, pp. 276–280, 2008. View at Google Scholar · View at Scopus
  4. D. R. Kaye, B. B. Storey, K. Pacak, P. A. Pinto, W. M. Linehan, and G. Bratslavsky, “Partial adrenalectomy: underused first line therapy for small adrenal tumors,” Journal of Urology, vol. 184, no. 1, pp. 18–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Scholten et al., “Evolution of surgical treatment of primary hyperparathyroidism in multiple endocrine neoplasia type 2A patients,” Endocrine Practice, vol. 21, pp. 1–25, 2010. View at Google Scholar
  6. S. M. Wilhelm, R. A. Prinz, A. M. Barbu, R. P. Onders, and C. C. Solorzano, “Analysis of large versus small pheochromocytomas: operative approaches and patient outcomes,” Surgery, vol. 140, no. 4, pp. 553–560, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. F. J. Pomares, R. Cañas, J. M. Rodriguez, A. M. Hernandez, P. Parrilla, and F. J. Tebar, “Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma,” Clinical Endocrinology, vol. 48, no. 2, pp. 195–200, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Raue and K. Frank-Raue, “Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management,” Hormones, vol. 8, no. 1, pp. 23–28, 2009. View at Google Scholar · View at Scopus
  9. S. M. Breckenridge, A. H. Hamrahian, C. Faiman, J. Suh, R. Prayson, and M. Mayberg, “Coexistence of a pituitary macroadenoma and pheochromocytoma—a case report and review of the literature,” Pituitary, vol. 6, no. 4, pp. 221–225, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. N. Schimke, “Multiple endocrine neoplasia: how many syndromes?” American Journal of Medical Genetics, vol. 37, no. 3, pp. 375–383, 1990. View at Google Scholar · View at Scopus
  11. A. F. Daly, M. A. Tichomirowa, and A. Beckers, “Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma,” Hormone Research, vol. 71, supplement 1, pp. 105–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Heliövaara, S. Tuupanen, M. Ahlsten et al., “No evidence of RET germline mutations in familial pituitary adenoma,” Journal of Molecular Endocrinology, vol. 46, no. 1, pp. 1–8, 2011. View at Publisher · View at Google Scholar
  13. A. Tahir, H. S. Chahal, and M. Korbonits, “Molecular genetics of the aip gene in familial pituitary tumorigenesis,” Progress in Brain Research, vol. 182, pp. 229–253, 2010. View at Google Scholar
  14. M. Vargiolu, D. Fusco, I. Kurelac et al., “The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2571–2578, 2009. View at Publisher · View at Google Scholar · View at Scopus